Troriluzole

DRUG14 trials

Sponsors

Global Coalition For Adaptive Research Inc., Biohaven Pharmaceuticals Inc., Biohaven Pharmaceuticals, Inc., Global Coalition for Adaptive Research, Dana-Farber Cancer Institute

Conditions

Alzheimer DiseaseBrain TumorGeneralized Anxiety DisorderGlioblastomaMelanomaMetastatic MelanomaObsessive Compulsive DisorderObsessive-Compulsive Disorder

Early Phase 1

A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma

RecruitingNCT06552260

Ugonma ChukwuekeBrain Tumor, Glioblastoma, Recurrent Glioblastoma

Start: 2025-02-19End: 2027-08-01Target: 27Updated: 2025-09-11

Phase 2

Trial in Adult Participants With Spinocerebellar Ataxia (SCA)

CompletedNCT02960893

Biohaven Pharmaceuticals, Inc.Spinocerebellar Ataxia Genotype Type 1, Spinocerebellar Ataxia Genotype Type 10, Spinocerebellar Ataxia Genotype Type 2 +5

Start: 2016-12-15End: 2024-09-20Updated: 2025-10-08

Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder

CompletedNCT03299166

Biohaven Pharmaceuticals, Inc.Obsessive-Compulsive Disorder

Start: 2017-12-19End: 2025-12-08Updated: 2026-01-22

Study of BHV-4157 in Alzheimer's Disease

CompletedNCT03605667

Biohaven Pharmaceuticals, Inc.Alzheimer Disease

Start: 2018-07-31End: 2021-12-23Updated: 2023-12-06

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

RecruitingNCT03970447

Global Coalition for Adaptive ResearchGlioblastoma

Start: 2019-07-30End: 2030-06-01Target: 2250Updated: 2026-04-03

Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets

TerminatedNCT04899921

Dana-Farber Cancer InstituteMelanoma, Metastatic Melanoma

Start: 2021-06-30End: 2023-05-29Updated: 2024-03-26

GBM AGILE Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent Glioblastoma (GBM)

RecruitingCTIS2024-511452-40-00

Global Coalition For Adaptive Research Inc.Oncology - Glioblastoma (GBM)

Start: 2025-09-12Target: 120Updated: 2025-09-12

Phase 3

Troriluzole in Adult Participants With Spinocerebellar Ataxia

Active, not recruitingNCT03701399

Biohaven Pharmaceuticals, Inc.Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 10 +5

Start: 2019-03-08End: 2026-06-30Updated: 2025-11-04

Randomized Trial of Adult Participants With Generalized Anxiety Disorder

CompletedNCT03829241

Biohaven Pharmaceuticals, Inc.Generalized Anxiety Disorder

Start: 2019-02-19End: 2020-05-08Updated: 2024-05-08

Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder

CompletedNCT04641143

Biohaven Pharmaceuticals, Inc.Obsessive-Compulsive Disorder

Start: 2020-12-22End: 2025-10-27Updated: 2026-01-07

Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder

CompletedNCT04693351

Biohaven Pharmaceuticals, Inc.Obsessive-Compulsive Disorder

Start: 2021-01-29End: 2025-04-29Updated: 2025-08-19

A Multicenter, Long-Term Open-Label Safety Study of Adjunctive Troriluzole in Subjects with Obsessive Compulsive Disorder

Active, not recruitingCTIS2024-512108-20-00

Biohaven Pharmaceuticals Inc.Obsessive Compulsive Disorder

Start: 2022-03-16Target: 43Updated: 2025-10-29

A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder

CompletedCTIS2024-514585-39-00

Biohaven Pharmaceuticals Inc.Obsessive Compulsive Disorder

Start: 2021-07-12End: 2025-01-11Target: 100Updated: 2025-01-29

Unknown Phase

Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA)

Biohaven Pharmaceuticals, Inc.SCA, Spinocerebellar Ataxias

Updated: 2026-01-09

Related Papers

TIP-10. Update on GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma

Neuro-Oncology2025-11-01

Archives of Psychiatry Research2025-08-25

Update on GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.

Journal of Clinical Oncology2025-05-281 citations

Prognostic value of plasma biomarkers for informing clinical trial design in mild-to-moderate Alzheimer's disease.

2025-05-021 citations

Measurement Properties of the Friedreich Ataxia Rating Scale in Patients with Spinocerebellar Ataxia.

2025-01-13

LTBK-02. EVALUATION OF PAXALISIB IN GBM AGILE PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

Neuro-Oncology2024-11-012 citations

CTNI-39. UPDATE ON GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

Neuro-Oncology2024-11-01

Metabolic Reprogramming in Cancer: Implications for Immunosuppressive Microenvironment.

2024-10-2728 citations

OS09.7.A GBM AGILE PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GBM: RESULTS OF FIRST EXPERIMENTAL ARM, REGORAFENIB

Neuro-Oncology2024-10-012 citations

KS03.5.A EVALUATION OF VAL-083 IN GBM AGILE, A PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

Neuro-Oncology2024-10-01

P27.11.A GLOBAL EXPANSION OF GBM AGILE: A PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

Neuro-Oncology2024-10-01

Psychometric Validation of the Modified Functional Scale for the Assessment and Rating of Ataxia (f-SARA) in Patients With Spinocerebellar Ataxia

The Cerebellum2024-06-129 citations

Evaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma.

Journal of Clinical Oncology2024-06-011 citations

Video-Based Kinematic Analysis of Movement Quality in a Phase 3 Clinical Trial of Troriluzole in Adults with Spinocerebellar Ataxia: A Post Hoc Analysis.

2024-05-308 citations

Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors

Communications Medicine2024-05-216 citations

Development and Validation of SCACOMS, a Composite Scale for Assessing Disease Progression and Treatment Effects in Spinocerebellar Ataxia.

2024-05-073 citations

Prognostic value of plasma biomarkers in a clinical trial of mild‐to‐moderate Alzheimer’s Disease

Alzheimer s & Dementia2023-12-01

CTNI-85. GBM AGILE PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GBM: RESULTS OF FIRST EXPERIMENTAL ARM, REGORAFENIB

Neuro-Oncology2023-11-0117 citations

P11.29.B UPDATE ON GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

Neuro-Oncology2023-09-01

Immune profiling in patients with glioblastoma treated with VT1021 in a phase I/II expansion study.

Journal of Clinical Oncology2023-06-013 citations

13 more papers not shown